FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Deborah Dunsire: Rexulti in agitation could potentially outperform blockbuster sales — MedWatch

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® to Treat Agitation Associated with Alzheimer's Dementia

Important News for Older Adults: FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease - Alliance for Aging Research

FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation

Leqembi Granted Full FDA Approval to Treat Early Alzheimer's Disease

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum

Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval

REXULTI® (brexpiprazole) Agitation associated with dementia due to Alzheimer's disease